The invention provides a series of anti-cancer peptide variants SEQ ID No: 2-15 and a pharmaceutical application of peptide variants. The peptide variants are obtained by carrying out a series of point mutation and specifically modifying two terminals on the basis of the sequence shown in SEQ ID No: 1; peptide variants, compared with wild-type peptide, have a stronger effect in killing tumor cells and broad pharmaceutical prospects.